Bioprocessing Unfiltered

CHI
  • 0.0 (0)
  • Biowissenschaften

Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

Folgen

  1. Episode: 9 - Jack Scarcelli on Moving Beyond One Host, One Vector, One Process for Today’s Cell Line Development

    2. Juni

    Episode: 9 - Jack Scarcelli on Moving Beyond One Host, One Vector, One Process for Today’s Cell Line Development

    In this episode of Bioprocessing Unfiltered, Jack Scarcelli, senior director and head of cell line development at Sanofi, speaks with host Hussain Dahodwala, professor of upstream process development at University of Maryland’s Institute of Bioscience and Biotechnology Research, to discuss technical and strategic challenges in the next gen cell line development in the biopharmaceutical industry. Scarcelli traces his career journey, shares lessons learned over a successful career, and offers thoughtful advice for early career scientists. Plus, some highlights from the upcoming Bioprocessing Summit in Boston in August and hope for collaboration to shape the future.   Links from this episode:   Bioprocessing Summit Sanofi    Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    22 Min.
  2. Episode: 8 - Jack Prior of Sanofi on AI Readiness in Biomanufacturing

    5. Mai

    Episode: 8 - Jack Prior of Sanofi on AI Readiness in Biomanufacturing

    In this episode of Bioprocessing Unfiltered, Jack Prior, head of process monitoring and data science and AI strategy at Sanofi, explores how AI has evolved from early expert systems to machine learning, generative AI, and agentic AI, and what that means for biomanufacturing today. He explains why digital transformation has not automatically created usable data, and why the real challenge is turning fragmented information from manufacturing systems into accessible, authentic, and analysis-ready data. Jack shares a practical framework for assessing data maturity and argues that the biggest near-term opportunity for AI is reducing friction in data engineering, troubleshooting, tech transfer, and decision support across bioprocessing organizations.  Links from this episode:   Bioprocessing Summit  Sanofi      Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    40 Min.
  3. Episode: 7 - Anurag Rathore on Platform Processes, Chromatography, and Expanding Education

    8. Apr.

    Episode: 7 - Anurag Rathore on Platform Processes, Chromatography, and Expanding Education

    Anurag Rathore, professor of chemical engineering at the Indian Institute of Technology Delhi, joins Bioprocessing Unfiltered with host Alois Jungbauer to discuss his long career in advancing bioprocessing engineering. Rathore shares his thoughts on chromatography, using platform processes to accelerate process development, how infinity capture can be a way to arrive at platform processes, and if there is a need for alternative methods. He also explores updates needed to the traditional curriculum of biochemical engineering—and if the next generation should know how to use AI and ML—and his view on bioprocess and development.  Links from this episode:   Bioprocessing Summit  Indian Institute of Technology Delhi  Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    32 Min.
  4. Episode: 6 - Fireside Chat: Innovation and Investment in Biomanufacturing of Future Medicine

    10. März

    Episode: 6 - Fireside Chat: Innovation and Investment in Biomanufacturing of Future Medicine

    At the most recent Bioprocessing Summit, David Y. H. Chang, CEO of Taiwan Bio-Manufacturing Company; Bo Wiinberg, Chief Business Development Officer of Novo Nordisk Foundation Cellerator; and Paul Lewus, Vice President of Site Operations at Amgen gathered for a fireside chat moderated by Ran Zheng, former CEO of Landmark Bio, to discuss the technologies and innovations shaping the future of biomanufacturing. The conversation explored upcoming trends, investment opportunities, and modalities into the next decade, as well as the question: how should the industry best prepare for all of it?  Links from this episode:   Bioprocessing Summit Landmark Bio Novo Nordisk Foundation Cellerator Taiwan Bio-Manufacturing Company (TBMC) Amgen    Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    55 Min.
  5. Episode: 5 - Andrew Sinclair Offers Insight on Optimizing Manufacturing and Operations, Part 2

    3. Feb.

    Episode: 5 - Andrew Sinclair Offers Insight on Optimizing Manufacturing and Operations, Part 2

    Picking up from their previous conversation on Bioprocessing Unfiltered, Andrew Sinclair, president and founder of BioPharm Services Ltd., and host William Whitford, founder of Oamaru BioSystems, discuss improving manufacturing efficiency, including process mass intensity and setting up parameters, and more on Sinclair’s long career and valuable experiences in the industry. Sinclair also shares advice on helping someone who cannot meet parameters, how to navigate new profusions, and default values that can help others with their processes.  Links from this episode:   Bioprocessing Summit   Biopharm Services    Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    35 Min.
  6. Episode: 4 - Andrew Sinclair Offers Insight on Optimizing Manufacturing and Operations - Part 1

    6. Jan.

    Episode: 4 - Andrew Sinclair Offers Insight on Optimizing Manufacturing and Operations - Part 1

    How can we optimize manufacturing and operations? In this episode of Bioprocessing Unfiltered, Andrew Sinclair, president and founder of Biopharm Services, provides insight from his 35-year-long career in the industry on the most significant ways data management and predictive modeling can improve efficiency during the manufacturing process. With host William Whitford, founder of Oamaru BioSystems, Sinclair delves into the history and impact of costs, how to handle evolving efficiencies, and why understanding definitions can be useful for speaking the language of regulators and rating organizations. Links from this episode: Bioprocessing Summit Biopharm Services  Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    23 Min.
  7. Episode: 3 - The Future of Gene Therapies and CDMOs with Philip Ramsey

    02.12.2025

    Episode: 3 - The Future of Gene Therapies and CDMOs with Philip Ramsey

    What is the future of gene therapies? In this episode of Bioprocessing Unfiltered, host Susan D’Costa, chief technical and commercial officer of Genezen, and Phillip Ramsey, CTO of Sangamo Therapeutics, discuss a variety of topics about gene therapies, including what will transform viral vector gene therapy, the evolving role of contract development and manufacturing organizations (CDMOs), and how gene editing in general fits into the broader gene therapy landscape. Plus, they cover the three key factors that are important in a relationship with a CDMO and the onslaught of different pressures that cell and gene therapies are currently under—and how to rekindle confidence in managing that pressure and tackling challenges.  Links from this episode:   Bioprocessing Summit Genezen Sangamo Therapeutics  Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    35 Min.
  8. Episode: 2 - Georges Belfort Discusses Breakthroughs in mRNA Purification

    04.11.2025

    Episode: 2 - Georges Belfort Discusses Breakthroughs in mRNA Purification

    What makes mRNA purification different from other bioprocessing methods? In this episode of Bioprocessing Unfiltered, host Alois Jungbauer, professor and head of biotechnology at the Institute of Bioprocess Science and Engineering at BOKU University, speaks with Georges Belfort, institute professor of chemical and biological engineering at Rensselaer Polytechnic Institute about his research in mRNA purification and his long, illustrious career in the industry, including the impact of his discoveries, the challenges encountered, and the lessons learned along the way. He also shares how he translates his research into products, what his lab is working on, and navigating competition from other companies.  Links from this episode:   Bioprocessing Summit RPI Chemical & Biological Engineering Rensselaer Polytechnic Institute BOKU University Institute of Bioprocess Science and Engineering BOKU University    Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    33 Min.
  9. Episode: 1 - Bo Wiinberg on Bridging Research and Trials with Cell-Based Therapies

    03.10.2025

    Episode: 1 - Bo Wiinberg on Bridging Research and Trials with Cell-Based Therapies

    Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinical and clinical development journeys, how Cellerator is creating innovative spaces in CMC and manufacturing to fulfill critical needs in the translational space, and what a sustainable global cell therapy manufacturing landscape looks in 5-10 years.  Links from this episode:   Bioprocessing Summit Landmark Bio Novo Nordisk Foundation Cellerator  Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

    22 Min.
  • 9 Folgen

Info

Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

Informationen

  • Erstellt von
    CHI
  • Jahre aktiv
    2025 - 2026
  • Folgen
    9
  • Bewertung
    Unbedenklich
  • Copyright
    © 2026 Bioprocessing Unfiltered
  • Sendungswebsite
    Bioprocessing Unfiltered